Portal de Periódicos da CAPES

TGF-β/SMAD canonical pathway induces the expression of transcriptional cofactor TAZ in liver cancer cells

2023; Elsevier BV; Volume: 9; Issue: 11 Linguagem: Inglês

10.1016/j.heliyon.2023.e21519

2405-8440

Diana G. Ríos-López, Ángeles C. Tecalco-Cruz, David Martínez-Pastor, Marcela Sosa‐Garrocho, Gustavo Tapia-Urzúa, Yuli Aranda-López, Bibiana Ortega-Domínguez, Félix Recillas‐Targa, Genaro Vázquez‐Victorio, Marina Macías‐Silva,

Hippo pathway signaling and YAP/TAZ

The TGF-β and Hippo pathways are critical for liver size control, regeneration, and cancer progression. The transcriptional cofactor TAZ, also named WWTR1, is a downstream effector of Hippo pathway and plays a key role in the maintenance of liver physiological functions. However, the up-regulation of TAZ expression has been associated with liver cancer progression. Recent evidence shows crosstalk of TGF-β and Hippo pathways, since TGF-β modulates TAZ expression through different mechanisms in a cellular context-dependent manner but supposedly independent of SMADs. Here, we evaluate the molecular interplay between TGF-β pathway and TAZ expression and observe that TGF-β induces TAZ expression through SMAD canonical pathway in liver cancer HepG2 cells. Therefore, TAZ cofactor is a primary target of TGF-β/SMAD-signaling, one of the pathways altered in liver cancer.